Background {#Sec1}
==========

Vector-borne viral diseases cause a substantial public health burden in tropical and sub-tropical regions. Their geographic distribution is expanding, due to many and complex factors, such as urbanization, climate change, land-use changes, human mobility, and vector range expansion \[[@CR1]\].

The Dengue virus (DENV) is a flavivirus (family *Flaviviridae*) transmitted to humans through *Aedes (Ae.) spp* mosquito bite. Dengue fever is typically characterized by fever, myalgia, arthralgia, rash, and sometimes severe and life-threatening clinical symptoms. Dengue global incidence has increased 30-fold in the last 50 years \[[@CR2]\], and areas with predominant circulation of a single DENV serotype have changed toward co-circulation of different virus serotypes \[[@CR3]\]. During the past decade, additional mosquito-borne viruses, including Chikungunya virus (CHIKV) and Zika virus (ZIKV), have successfully spread to geographical areas where only dengue epidemics used to be reported \[[@CR3]--[@CR8]\]. CHIKV is an alphavirus (family *Togaviridae*) that causes an acute febrile illness characterized by severe arthralgia, whereas ZIKV, another mosquito-borne flavivirus closely related to DENV, mostly causes mild fever, joint pain, conjunctivitis, and rash \[[@CR3]\]. As for DENV, CHIKV and ZIKV are transmitted between humans by *Ae.* species mosquitoes \[[@CR9], [@CR10]\]. Since 2004, CHIKV has caused epidemics in Africa, Asia, and Indian Ocean islands. In 2007 an outbreak of chikungunya originated from an imported case coming from India occurred in Italy, causing more than 200 cases of disease \[[@CR11]\]. In December 2013, CHIKV was notified in the Caribbean and has since spread to several countries in the Americas \[[@CR7], [@CR12]\]. The first outbreak of ZIKV outside Africa and Asia was reported in 2007 in the Yap State, Federated States of Micronesia \[[@CR13]\]. Subsequently, in 2013, this virus reappeared in French Polynesia and then spread throughout the Pacific. In the early 2015, the first local transmission of ZIKV was reported in Brazil \[[@CR14]\]. Since then, the infection has rapidly spread throughout South America, Central America, and the Caribbean \[[@CR8], [@CR15], [@CR16]\], and recently in Florida, USA \[[@CR17]\]. ZIKV, previously thought to be associated with a mild clinical disease, was found to be associated with a 20-fold increase in the Guillain-Barrè syndrome incidence following the French Polynesia outbreak \[[@CR18]\]. Moreover, the report of a possible association between ZIKV infection and an epidemic of microcephaly among neonates in Brazil has attracted global attention, and has led the World Health Organization (WHO) to declare the ZIKV epidemic as a global public health emergency on February, 1st 2016 \[[@CR19]\]. In the meanwhile, evidence supporting the association between ZIKV infection and neonatal microcephaly and other birth defects has increased \[[@CR20]--[@CR25]\].

Imported cases of illness due to DENV and CHIKV, and more recently ZIKV, are reported every year among travelers returning from endemic regions \[[@CR26]--[@CR28]\]. In areas where competent vectors are present, the risk of autochthonous transmission of these vector-borne pathogens is particularly high \[[@CR11], [@CR29]\]. Thus, epidemiological and laboratory surveillance is crucial to rapidly identify imported cases in order to introduce measures to reduce risks for public health. The aim of the present study is to present data on imported infections in Italy, diagnosed at the National Reference Laboratory for Arboviruses (NRLA) in the period from July 2014 to October 2015, mainly focusing on diagnostic issues, countries of origin of the infections, and viral strains involved in the imported cases.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

Samples of patients visited/hospitalized with a suspected DENV/CHIKV/ZIKV infection, collected from July 2014 through October 2015, were analyzed. A case-report form containing information about age, sex, countries visited, travel dates, and date of onset of symptoms was completed for each patient. Samples were collected and sent to the NRLA at the Istituto Superiore di Sanità in Rome from several Italian Hospitals, in agreement with the National Plan on human surveillance of imported and autochthonous vector-borne diseases (CHIKV, DENV, ZIKV, and West Nile virus---WNV) \[[@CR30], [@CR31]\]. Samples were sent also from Regional Reference Laboratories for Arboviruses involved in the surveillance National Plan for diagnostic confirmation and/or with the aim of a cross-evaluation of the diagnostic methods used in different laboratories. ELISA IgM and real time PCR tests were performed for a first line diagnosis. Plaque Reduction Neutralization Tests (PRNTs) were performed to confirm positive results obtained by ELISA tests, and to discriminate between closely related viruses.

Serological assays {#Sec4}
------------------

### ELISA IgM {#Sec5}

IgM antibodies against DENV, CHIKV, and ZIKV were detected in patients serum samples using commercial IgM-capture ELISA systems (Focus Diagnostics Dengue Virus IgM Capture, DxSelect™, California, USA, NovaLisa® Chikungunya IgM μ-capture ELISA, NovaTec Immundiagnostica GmbH, Germany, Euroimmun Anti-Zika Virus IgM ELISA, Luebeck, Germany). Absorbance was measured at 450 nm using an ELISA reader, according to manufacturer's instructions. Sample optical density readings were compared with reference cut-off OD readings to determine results. Index values \>1.00 for DENV, \> 11.00 for CHIKV, and \> 1,1 for ZIKV were considered presumptive for the presence of IgM antibodies.

### Plaque Reduction Neutralization test (PRNT) {#Sec6}

The assay was performed in six-well tissue culture plates with subconfluent VERO cell monolayers (approximately 70% confluence). The following viruses were used: serotype 2 DENV (NGB strain), a CHIKV strain isolated from a patient during the 2007 Italian outbreak \[[@CR11]\], and ZIKV H/PF/2013 strain of the Asian genotype (kindly provided by Dr. Isabelle Leparc-Goffart of the French National Reference Center on Arboviruses in Marseille) \[[@CR32]\]. Infectivity titration of each viral strain was performed by plaque assay using VERO cells. Patients sera were diluted 1:10 in serum-free maintenance medium, heat-inactivated, and titrated in duplicate in twofold dilution steps. Equal volumes (100 μl) of DENV/CHIKV/ZIKV dilution containing approximately 80 Plaque Forming Units (PFU), and serum dilutions, were mixed, and incubated overnight at 4 °C. Subsequently, VERO cells plates were infected with 200 μl/well of virus-serum mixtures in duplicate. After 1 h incubation at 37 °C and 5% CO~2~, the inocula were aspirated and the wells were overlayed with a mixture of one part 2% Gum Tragacanth and one part of supplemented medium (2× MEM, 2.5% inactivated FCS and 2% 1 M HEPES). The plates were incubated at 37 °C and 5% CO~2~ for 2 (CHIKV) - 7 (DENV) - 4 (ZIKV) days, and then were stained with 1.5% crystal violet. A titration of CHIK/DEN/ZIK viruses with three dilutions in duplicate (the working dilution, 1:2 and 1:8 dilutions) was performed in each assay and used as a control for the assay. Neutralizing antibody titers were calculated as the reciprocal of the serum dilution that gave a 50 or 80% reduction of the number of plaques (PRNT50/PRNT80), as compared to the virus control. PRNT80 ≥ 10 were considered positive, while PRNT50 ≥ 10 were considered as border line (b.l.).

Molecular diagnosis {#Sec7}
-------------------

### RNA extraction and Real Time PCRs {#Sec8}

Molecular tests were performed on acute sera of DENV/CHIKV/ZIKV-suspected patients.Viral RNA was extracted from 140 μl of serum sample by using QIAmp viral RNA Mini kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer's instructions, and then stored at -80 °C until further processing. The RNA was amplified by real time PCR for CHIKV, DENV, and/or ZIKV detection. The primers and probes used in this study are listed in Table [1](#Tab1){ref-type="table"} \[[@CR11], [@CR33], [@CR34]\]. All real time PCR assays were performed by using the RealTime ready RNA Virus Master mix (Roche Diagnostics, Basel, CH), according to the manufacturer's protocol, and CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad).Table 1Primers and probes for the molecular diagnosisPrimers and ProbesSequence (5'- 3')ReferenceDenSGGATAGACCAGAGATCCTGCTGT\[[@CR33]\]DenAs + DenAs1CATTCCATTTTCTGGCGTTC + CAATCCATCTTGCGGCGCTCDenPFAM-CAGCATCATTCCAGGCACAG-TAMRAChikSTGATCCCGACTCAACCATCCT\[[@CR11]\]ChikAsGGCAAACGCAGTGGTACTTCCTChikPFAM-TCCGACATCATCCTCCTTGCTGGC-Black Hole Quencher 1Zvf1086CCGCTGCCCAACACAAG\[[@CR34]\]Zvr1162cCCACTAACGTTCTTTTGCAGACATZvP_11076FAM-AGCCTACCTTGACAAGCAGTCAGACACTCAA-TAMRA

### Amplification and sequencing from viral RNA {#Sec9}

For DENV and CHIKV nucleic acid detection and genotyping, Reverse Transcription (RT)-PCR followed by nested PCR amplification was performed. An amplicon of 434 bp in the E gene region and an amplicon of 536 bp in the E1 structural glycoprotein coding gene region were obtained for DENV an CHIKV, respectively. The primers used for RT-PCR plus nested PCR and sequencing are listed in Table [2](#Tab2){ref-type="table"} \[[@CR35], [@CR36]\]. SuperScript One-step RT-PCR with Platinum Taq kit (Invitrogen, Gaithersburg, MD) and Platinum PCR SuperMix kit (Invitrogen) were used for RT-PCR and nested PCR, respectively. PCR products were purified by QIAquick PCR Purification Kit (Qiagen) and were sequenced on both strands by using nested forward and reverse primers.Table 2Primers for DENV and CHIKV amplification and sequencingPrimersSequence (5'- 3')ReferenceRT-PCR:\[[@CR35]\] DEULTGGCTGGTGCACAGACAATGGTT DEURGCTGTGTCACCCAGAATGGCCATNested PCR: DENULGATCTCAAGAAGGAGCCATGCA DENURATGGAACTTCCCTTCTTGAACCART-PCR:\[[@CR36]\] CHIK 10264 FGGCGCCTACTGCTTCTG CHIK 11300RCGACACGCATAGCACCSCNested PCR: CHIK 10564 FCCCTTTGGCGCAGGAAGAC CHIK 11081RGACTTGTACGCGGAATTCGG

Phylogenetic analysis {#Sec10}
---------------------

The sequences obtained were aligned with other DENV/CHIKV sequences available in the GenBank database (accession numbers are reported in the phylogenetic trees), by using the ClustalW program ([www.clustal.org](http://www.clustal.org)) \[[@CR37]\]. Alignments were manually edited with the Bioedit program \[[@CR38]\]. Nucleotide Tamura-Nei model and the Neighbour-Joining method was used to construct the phylogenetic trees \[[@CR39]\]. The Neighbour-Joining method was implemented by using MEGA version 6.06 ([www.megasoftware.net](http://www.megasoftware.net)) \[[@CR40]\]. The robustness of branching patterns was confirmed with a bootstrap analysis using 1000 replicates.

Results {#Sec11}
=======

Dengue, Chikungunya and Zika diagnostic tests results, and areas of origin of the imported infections {#Sec12}
-----------------------------------------------------------------------------------------------------

Samples collected from 180 patients visited/hospitalized with a suspected DENV/CHIKV/ZIKV infection were analyzed. Of the patients, 50,6% were males, median age was 38 years (range 1--80 years). For 116 patients for whom the information about the date of symptoms onset and/or hospitalization was available, the median lag time before sample collection was 8 days (range 2--102 days, mean ± standard deviation: 15,47 ± 18,24 days). Two serum samples (acute phase and convalescence phase) were available from 27 patients. Samples were sent to the NRLA from several Italian Regions (Friuli Venezia Giulia, Lombardia, Piemonte, Liguria, Toscana, Umbria, Lazio, Abruzzo, Campania, Sardegna, Calabria e Sicilia). Most of the samples were collected during the summertime, from June to September, when the surveillance is increased because of vector activity.

On the base of diagnostic tests results, and clinical and epidemiological data, each case was defined as confirmed, probable, possible or not confirmed, according to the criteria shown in Table [3](#Tab3){ref-type="table"}.Table 3Case definition on the bases of the diagnostic test resultsConfirmedPCR positive and/or IgM positive plus PRNT positive^a^, and/or seroconversion or four fold increase in neutralizing antibody titers in two consecutive samples.ProbableIgM positive plus PRNT border line^b^ in acute samples^c^.PossibleIgM negative and PRNT positive/border line, or IgM positive but PRNT negative in acute samples.Not confirmedIgM positive and PRNT negative in late/convalescent samples, or PRNT positive without an increase in the titer in two consecutive samples.^a^PRNT80 ≥ 10: positive^b^PRNT50 ≥ 10: border line (b.l.)^c^These cases were classified as possible if PRNT b.l. results were obtained toward different viruses

In the study period, a total of 157 patients were tested for DENV, 97 for CHIKV and 16 for ZIKV (Table [4](#Tab4){ref-type="table"}).Table 4DENV, CHIKV and ZIKV diagnosis in the period from July 2014 to October 2015TotalConfirmedProbablePossibleNot confirmedDENV diagnosis15768123344CHIKV diagnosis973561442ZIKV diagnosis164^a^03^b^9Dual diagnosis DENV/CHIKV76: two cases of possible co-infections.DENV: 18/76 (of which two CHIKV confirmed and one CHIKV possible cases)CHIK: 20/76 (of which two DENV confirmed and 6 DENV possible cases)^a^The diagnosis of one of these cases was performed in Germany after we excluded DENV and CHIKV infections (ref). One was a case of autochthonous (most likely sexual) transmission (ref)^b^Of these, two were probable cases of past ZIKV infections (PRNT positives and IgM negatives). One showed instead a PRNT b.l. result for ZIKV, which was probably due to cross reactivity of DENV specific antibodies

Overall, 68 DENV cases (plus 12 probable cases), 35 CHIKV cases (plus 6 probable cases), and 4 ZIKV cases \[[@CR27], [@CR41]\] were confirmed, plus two cases of ZIKV past infection. For 76 patients, diagnostic tests both for DENV and for CHIKV were performed, and 2 cases of possible co-infections were detected. Clinical features of DENV, CHIKV and ZIKV confirmed/probable cases are shown in Table [5](#Tab5){ref-type="table"}.Table 5Clinical features of DENV, CHIKV and ZIKV confirmed/probable casesSymptomsDENV confirmed and probable cases presenting with the symptom^a^CHIKV confirmed and probable cases presenting with the symptom^a^ZIKV confirmed and probable cases presenting with the symptom^a^Fever (≥38 °C)93,2%92,6%75,0%Arthralgia71,2%96,3%75,0%Rash33,9%66,7%100,0%Asthenia76,3%70,4%25,0%Headache62,7%37,0%0,0%Myalgia52,6%63,0%25,0%Retro-orbital pain32,2%11,1%0,0%Meningoencephalitis1,7%3,7%0,0%Others10,2%^b^3,7% ^c^0,0%^a^Symptoms were known for 59, 27 and 4 DENV, CHIKV and ZIKVV cases, respectively^b^diarrhea, vomit, leuco-thrombocytopenia^c^symptoms persisting for longer than 30 days

The area of origin of the suspected imported cases was known for 62 DENV, 30 CHIKV, and 4 ZIKV confirmed/probable cases DENV cases were imported from many different countries in all continents except Europe. Among DENV confirmed/probable cases, 59.7% were from Asia, 17.7% from Central and South America, 11.3% from the Caribbean, 6.5% from Africa, and 4.8% from Oceania. As expected, because of the recent CHIKV epidemics in the Americas, among the CHIKV confirmed/probable cases, 53.3% were from the Caribbean, 36.7% were from Central and South America, and only 10.0% were from Asia or Africa. Two ZIKV confirmed infections had been acquired in Brazil, one in March \[[@CR27]\] and one in May, 2015, while one had been acquired in Thailand in 2014, and one was an autochthonous case likely due to sexual transmission \[[@CR41]\].

Serological diagnosis of DENV, CHIKV and ZIKV infections {#Sec13}
--------------------------------------------------------

### ELISA IgM tests {#Sec14}

Results of ELISA IgM tests are summarized in Table [6](#Tab6){ref-type="table"}.Table 6DENV/CHIKV/ZIKV ELISA IgM tests resultsELISA IgM: positives/testedEstimated proportion of false positive and false negative test resultsDENV (Focus Diagnostics Dengue Virus IgM Capture, DxSelect™)55/1278/55 (14.5%) false positives8/72 (11.1%) false negativesCHIKV (NovaLisa® Chikungunya IgM μ-capture ELISA, NovaTec Immundiagnostica)31 + 3 b.l./861 b.l./86 (1,2%) false positives5/52 (9,6%) false negativesZIKV (Euroimmun IgM ELISA)3/5

DENV ELISA IgM test was performed for 127 of 157 patients tested for DENV, with 55 positive results; for 14.5% of the ELISA IgM positive patients, a final diagnosis of confirmed or probable DENV infection was not done after considering all laboratory findings and available epidemiological data. These cases are likely to represent false positive IgM ELISA results. Conversely, 11.1% of the ELISA IgM negative patients were diagnosed as confirmed DENV cases on the basis of other tests (PCR positivity) and/or of IgM results obtained by the hospital/laboratory where the sample had been collected (not shown); they were considered as false negatives. Of note, of the DENV suspected cases coming to our laboratory with a positive IgM result obtained in the hospital/laboratory where the sample had been collected (*n* = 53) (not shown), 24.5% (13/53) could not be confirmed by PRNT nor by molecular tests.

CHIKV ELISA IgM test was performed for 86 of 97 patients tested for CHIKV, with 3 b.l. results, and 31 positive results; all positive ELISA IgM results and two of the b.l. were confirmed by a positive or b.l. PRNT result. Among 52 CHIKV ELISA IgM negative samples, 13 were positive and 4 b.l. in PRNT: of these, at least 5 (9.6%) were considered to be associated with a recently acquired infection, based on clinical and epidemiological data, and thus estimated as probable false-negative ELISA results. Of the CHIKV suspected cases coming to our laboratory with a positive IgM result obtained in the hospital/laboratory where the sample had been collected (*n* = 27) (not shown), 11.1% (3/27) were classified as not confirmed after evaluation of all laboratory findings. ZIKV IgM test was performed for 5 patients, all with a PRNT positive result for ZIKV: 3 were positive, and were thus considered as recent, confirmed, ZIKV infections, while the two IgM negatives were considered as past infections.

Overall, 94 DENV and 40 CHIKV ELISA IgM results could be compared with the IgM results obtained with different methods in the hospital/laboratory of origin of the samples (not shown): concordant results were obtained in 81.9 and 87.5% of cases for DENV and CHIKV, respectively.

### PRNTs {#Sec15}

PRNTs results are summarized in Table [7](#Tab7){ref-type="table"}: neutralizing antibodies were detected in 79/157 (50.3%) of patients tested for DENV, in 47/97 (48.4%) of patients tested for CHIKV, and in 5/15 (33,3%) of patients tested for ZIKV. In 26/79 (32,9%) of DENV PRNT positive patients, 10/47 (21,2%) of CHIKV PRNT positive patients, and 2/5 (40%) of ZIKV PRNT positive patients, both molecular tests and ELISA IgM gave negative results: these subjects had probably acquired a DENV and/or CHIKV infection in the past, which was not associated with the recent/ongoing illness. A b.l. PRNT result was obtained for 31 of 157 DENV tested patients. Of these, 10 (32.3%) were classified as confirmed cases, since the viral genome could be detected in the same sample, and/or a fully positive PRNT result was obtained in a second, convalescent sample. Moreover, 12 (38.7%) were classified as probable cases, since a positive ELISA IgM results was obtained in the same sample. Finally, 9 (29%) PRNT b.l. results were obtained from cases defined as possible, which were not associated with any other positive result (*n* = 5), and/or associated with a confirmed infection by a closely related Flavivirus (ZIKV, *n* = 3), and/or in cases showing b.l. PRNT results also for different viruses (such as CHIKV and WNV, *n* = 3), suggesting a broad and non DENV-specific cross-reactivity. With respect to CHIKV diagnosis, a b.l. PRNT result was obtained for 11 (11.3%) of 97 CHIKV tested patients: one from a confirmed case, 4 from probable cases, and 6 which were classified as possible cases, since they were not associated with positive results in other CHIKV tests, and, in 3 cases, presented b.l. PRNT results also for different viruses (such as DENV and WNV). Finally, one b.l. PRNT result was obtained for ZIKV, in a sample of a DENV confirmed case.Table 7DENV/CHIKV/ZIKV PRNTs resultsPRNT positives/testedPRNT border line/testedDENV79/157 (50.3%)31/157 (19,7%)10/31 (32.3%): confirmed cases12/31 (38.7%): probable cases9/31 (29%): possible casesCHIKV47/97 (48.4%)11/97 (11,3%)1/11 (9%): confirmed case4/11 (36,4%): probable cases6/11 (54,6%): possible casesZIKV5/15 (33,3%)1/15 (6,7%)possible case (probable cross reactivity of DENV specific neutralizing antibodies)

Molecular diagnosis of DENV and CHIKV infections, and phylogenetic analysis of viral sequences {#Sec16}
----------------------------------------------------------------------------------------------

For DENV diagnosis, 25 of 132 (18.9%) samples tested by real time PCR gave a positive result. All PCR positive samples (for which the time from the onset of symptoms was known), had been collected within 8 days from the onset of symptoms (mean ± standard deviation: 4.71 ± 1.76 days). For CHIKV diagnosis, only 2/76 (2.6%) samples tested by real time PCR gave a positive result, which had been collected 3 days after the onset of symptoms. All samples analyzed for ZIKV by real time PCR gave negative results.

Among all samples collected within 8 days from the onset of symptoms, CHIKV viral genome was detected in 7.7% (2/26) of the samples (22.2% of confirmed/probable cases), and DENV viral genome in 36.8% (21/57) of tested samples (53.8% of confirmed/probable cases). These data may suggest a longer duration of viremia in DENV infection compared to CHIKV infection.

Sequences were obtained for 22 of the DENV PCR positive samples, and for the 2 CHIKV PCR positive samples. Both nucleic acid and translated amino acid sequences were aligned with GenBank sequences of isolates with known dates and locations, and phylogenetic analysis was performed. Viral strains and genotypes, locations of origin, year of the infections, and Gene Bank accession numbers are summarized in Tables [8](#Tab8){ref-type="table"} (sequences characterized in this study) and Table [9](#Tab9){ref-type="table"} (reference sequences). As shown in Fig. [1a,b,c](#Fig1){ref-type="fig"} and d, DENV strains of all the four serotypes were identified (11 DENV-1, 8 DENV-2, two DENV-3 and one DENV-4 strains). Within the DENV-1 serotype, 4 strains grouped together with the Asian lineage (genotype I), 3 with the South Pacific lineage (Genotype IV) and 4 with African/American lineage (Genotype V), with bootstrap values ≥ 97 (Fig. [1a](#Fig1){ref-type="fig"}). Most of DENV-1 sequences (from patients S2015-423, S2015-475, S2014-376, S2015-510, S2015-470, S2015-425, S2015-481, S2015-458, S2015-431) showed a high similarity with GenBank strains known to circulate in the areas of origin of the imported infections (88--98% homology at nucleic acid level and 100% at amino acid level). In contrast, two of our DENV-1 sequences showed a higher degree of divergence when compared to DENV-1 sequences available in Gene Bank. A strain from Philippines, identified in the patient S2014-383, showed the highest similarity (88% homology at nucleic acid level and 93% at amino acid level), with two strains from Philippines collected in previous years (acc. n° JN415517 collected in 2010; acc. n° KR919819 collected in 2012). Moreover, the phylogenetic analysis of the strain S2014-358 from Thailand, showed the higher similarity (86% homology at nucleic acid level and 92% at amino acid level) with a Gene Bank Thai strain collected in 2010 (acc. n° JN415528). The strain S2014-358 showed the same 92% similarity at amino acid level also with other Thai strains collected in 2013 (acc. n° KJ545455 and KF887994). In Fig. [1b](#Fig1){ref-type="fig"} is reported the DENV-2 tree: 7 out of 8 strains (S2014-368, S2015-409, S2015-465, S2014-482, S2015-477, S2014-478 and S2015-512) clustered in the Cosmopolitan genotype: 4 of them (S2015-409, S2015-465, S2015-478, S2015-482), from Thailand and India, showed a high similarity with Indian isolates sequences (2001-DQ448236 and 2011-KF364514) both at nucleic acid and amino acid level (90--98% and 100% respectively). The S2014-382 sequence, from Santo Domingo, clustered in the American/Asian genotype, showing a strong homology (85 and 100% in nucleic and amino acid composition, respectively) with the strain collected in Puerto Rico in 2013 (acc. n° LN870427). The two DENV-3 strains identified in this study (S2014-339 from Cuba, and S2015-517 from unknown geographic area) clustered in genotype III, showing 93--100% of identity with the GenBank strains collected in Central American and Caribbean areas (acc. n° DQ341204 and level (Fig. [1c](#Fig1){ref-type="fig"}). The DENV-4 sequence (S2015-466, from Thailand) showed a strong homology with an isolate collected in 2013 from Myanmar area (acc. n° KJ470765) (similarity of 90 and 100% at nucleic and amino acid level, respectively), and distance values of 73--80% at nucleic acid level and 83--93% at amino acid level, with other sequences of different years from Thailand (acc. n° AY618990 collected in 1991, AY618980 collected in 1998, AY618992 collected in 2001, and EU448454 collected in 2007) (Fig. [1d](#Fig1){ref-type="fig"}). CHIKV sequences obtained from patients S2015-416 (for which the geographic area of origin of the infection was not known) and S2015-422, from Colombia, were aligned with 30 GenBank sequences with known dates and locations. From the analysis of the phylogenetic tree, the two sequences were shown to belong to the Asian genotype (Fig. [2](#Fig2){ref-type="fig"}). The S2015-416 sequence showed a 100% identity both at nucleic and amino acid level with an isolate collected in 2008 in Indonesia (acc. n° KC879577). The S2015-422 sequence showed the strongest homology with a Brazilian isolate (acc. n° KP164572) (98 and 96% similarity at nucleic and amino acid level, respectively).Table 8DENV and CHIKV sequences characterized in this studyIsolate IDTravel locationGenotypeYear isolatedGenBank accession no.DENV-1 S2014-358ThailandI-Asian2014LN870423 S2014-376Bali, IndonesiaI-Asian2014LN870425 S2015-510?I-Asian2015LN999960 S2015-460French_PolynesiaI-Asian2015LN999954 S2015-475PhilippinesIV-South Pacific2015LN999955 S2015-423OceaniaIV-South Pacific2015LN879497 S2014-383Manila, PhilippinesIV-South Pacific2014LN870426 S2015-431MaldivesV-African/American2015LN879498 S2015-458MaldivesV-African/American2015LN999951 S2015-481MexicoV-African/American2015LN999958 S2015-425HaitiV-African/American2015LN879499DENV-2 S2014-368?Cosmopolitan2014LN870428 S2015-477MaldivesCosmopolitan2015LN999956 S2015-512?Cosmopolitan2015LN999961 S2015-409ThailandCosmopolitan2015LN999950 S2015-465ThailandCosmopolitan2015LN999952 S2015-482IndiaCosmopolitan2015LN999959 S2015-478Thailand and CambodiaCosmopolitan2015LN999957 S2014-382Santo Domingo, Dominican RepublicAmerica/Asian2014LN870427DENV-3 S2015-517?III2015LN999962 S2014-339CubaIII2014LN870424DENV-4 S2015-466ThailandI2015LN99995CHIKV S2015-416?Asian2015LN879501 S2015-422ColombiaAsian2015LN879500 Table 9DENV and CHIKV reference sequencesVirus strainLocationGenotypeYear isolatedGenBank accession no.DENV-1 NC14-17042014-4554New CaledoniaI-Asian2014KM212960 China/GD-D13001ThailandI-Asian2013KJ545455 DENV-1/8/Thailand/01/2013ThailandI-Asian2013KF887994 Khabar 2759Khabarovsk, Far East, RussiaI-Asian2012KJ417841 SL_2012_GS0319Sri-LankaI-Asian2012KJ26662 MKS-WS81IndonesiaI-Asian2010KC762639 D1/Vietnam/1012aTwViet NamI-Asian2010JF967953 Thailand 2010ThailandI-Asian2010JN415528 D1/IDN/Bali_033/2010IndonesiaI-Asian2010KM216676 -CambodiaI-Asian1998AF309641 GZ/80ChinaI-Asian1980AF350498 PUO 359ThailandI-Asian1980AF425630 16007ThailandII-Thailand1964AF180817 TH-SMANThailandII-Thailand1954D10513 P72-1244MalaysiaIII-sylvatic1972EF457905 D1/Hu/Philippines/NIID13/2016PhilippinesIV-South Pacific2016LC128301 FI/DB170/2014FijiIV-South Pacific2014KM279390 Phil2012PhilippinesIV-South Pacific2012KR919819 Philippines 2010PhilippinesIV-South Pacific2010JN415517 WS01/190801-769SamoaIV-South Pacific2001JQ655095 A88IndonesiaIV-South Pacific1988AB074761 AUS HCS1AustraliaIV-South Pacific1983AF425611PRS 228682PhilippinesIV-South Pacific1974AF425627 Guangzhou/2014/4ChinaV-African/American2015KT751343 Wenzhou-Human-1ChinaV-African/American2014KR024708 9/D1/Del/2013IndiaV-African/American2013KU166895 AO/DB132/2013AngolaV-African/American2013KM277610 DENV-1/NI/BID-V7696/2012NicaraguaV-African/American2012KF973475 ARC-73-12Puerto RicoV-African/American2012KF444913 D1/Mexico/Ixtaczoquitlan/17/2007MexicoV-African/American2007HM171564 ThD1_0673_80ThailandV-African/American1980AY732474 715393IndiaV-African/American1971JF297579 IBH 28328NigeriaV-African/American1968AF425625DENV-2 SG(EHI)D2/18944Y13SingaporeCosmopolitan2013KR779784 D2/IDN/Lombok_087/2012Bali, IndonesiaCosmopolitan2012KM216718 D2/IDN/Bali_103/2012Bali, IndonesiaCosmopolitan2012KM216731 D2/THA/086/2012ThailandCosmopolitan2012KM216717 D2/TLS/Timor_078/2012East TimorCosmopolitan2012KM216712 D2/IDN/Bali_108/2012IndonesiaCosmopolitan2012KM216736 12/GZ/12851ChinaCosmopolitan2012KF060919 D2/IDN/Bali_075/2011Bali, IndonesiaCosmopolitan2011KM216709 D2/IN/RGCB921/2011IndiaCosmopolitan2011KF364514 10/GZ/11864ChinaCosmopolitan2010JN009092 Philippines 2010bPhilippinesCosmopolitan2010JN568265 D2/IDN/Jakarta_060/2010IndonesiaCosmopolitan2010KM216708 SG(EHI)D2/63481Y10SingaporeCosmopolitan2010JN030340 DENV-2/VN/BID-V735/2006Viet NamCosmopolitan2006EU482672 D2/SG/05K3330DK1/2005SingaporeCosmopolitan2005EU081178 GWL177 INDI-01IndiaCosmopolitan2001DQ448236 2784-DF-11/18/2002TaiwanCosmopolitan2002DQ645556 MD922Viet NamAsian II2003GU434156 40247BrazilAsian II1990L10041 ThD2_0284_90ThailandAsian II1990DQ181801 PR/DB189/2013Puerto RicoAmerican/Asian2013KM279409 DR59/01Dominican RepublicAmerican/Asian2001AB122022 Cuba115/97CubaAmerican/Asian1997AY702050 IQT-1950PerùAmerican1995DQ917242 D2/TO/UH04/1974TongaAmerican1974HM582117 Laos 2010LaosAsian I2010JN568244 D2/Myanmar/1007aTwMyanmarAsian I2010JF968026 D2/LAO/043/2010LaosAsian I2010KM216697 D2/Laos/1007aTwLaosAsian I2010JF968021 DENV-2/KH/BID-V2062/2007CambodiaAsian I2007GQ868624 Myan0207a/TwMyanmarAsian I2002DQ518651 DENV-2/TH/BID-V2311/2001ThailandAsian I2001FJ744725 GD08/98ChinaAsian I1998FJ196851 ThD2_0168_79Bangkok, ThailandAsian I1979DQ181805 DAK Ar 2022Burkina Fasosylvatic1980DQ917247 DAK Ar 2039Burkina Fasosylvatic1980DQ917246DENV-3 D3/IDN/Bali_007/2010IndonesiaI2010KM216737 D3/Malaysia/1012bTwMalaysiaI2010JF968112 H87PhilippinesI1987M93130 80-2ChinaI1980AF317645 D3-73NIIDJapanI1973AB111085 LN2632MalaysiaII1999AF147459 D89-273ThailandII1989AY145715 PaH881/88ThailandII1988AF349753 ThD3_0046_83ThailandII1983AY676358 ThD3_0040_80ThailandII1980AY676359 ThD3_0033_74ThailandII1974AY676360 D3BR/ST14/04BrazilIII2004DQ118882 -SingaporeIII2004AY662691 D3PY/AS12/02ParaguayIII2002DQ118884 BR74886/02BrazilIII2002AY679147 Cuba_167_2001CubaIII2001KT726341 Cuba580/01CubaIII2001AY702030 D3/H/IMTSSA-SRI/2000/1266Sri LankaIII2000AY099336 00-28-1HuNIIDCambodiaIII2000AB111081 6883/YUCATAN-MX/97YucatanIII1997DQ341204 1339Puerto RicoIV1997AY146761 Human, Tahiti 1965TahitiIV1965L11439DENV-4 D4/RL196/Myanmar/2013MyanmarI2013KJ470765 D4/Thailand/0702aTwThailandI2007EU448454 D4/Cambodia/0509aTwCambodiaI2005EU448455 ThD4_0485_01ThailandI2001AY618992 ThD4_1142_98ThailandI1998AY618980 ThD4_0348_91Bangkok, ThailandI1991AY618990 SPH317947BrazilII2011JN092553 DENV-4/VE/BID-V1156/2007VenezuelaII2007GQ868645 DENV-4/CO/BID-V3412/2005ColombiaII2005CQ868585 D4MY02-26658MalaysiaII2002FN429922 8976/95SingaporeII1995AY762085 D4/PR/M35/1985Puerto RicoII1985GU318316 ThD4_0476_97Bangkok, ThailandIII1997AY618988 ThD4_0017_97Bangkok, ThailandIII1997AY618989 P75-514MalaysiaIV1975AF231723 P73-1120MalaysiaIV1973AF231724CHIKV 10Mdy105MyanmarEast Central South African2010KF590567 GD139ChinaEast Central South African2010HQ846358 TN06310IndiaEast Central South African2010HM159388 CU-Chik_OBFThailandEast Central South African2009GU908223 0901aTwMalaysiaEast Central South African2009FJ807895 0812bTwMalaysiaEast Central South African2008FJ807893 CU-Chik10ThailandEast Central South African2008GU301780 FD080178ChinaEast Central South African2008GU199352 0810aTwBangladeshEast Central South African2008FJ807898 SGEHICHT077808SingaporeEast Central South African2008FJ445484 ITA07-RA1ItalyEast Central South African2007EU244823 DRDE-07IndiaEast Central South African2007EU372006 LR2006_OPY1ReunionEast Central South African2006DQ443544 0611aTwSingaporeEast Central South African2006FJ807896 SL11131Sri LankaEast Central South African2006AB455493 06-027ReunionEast Central South African2005AM258993 UgAg4155UgandaEast Central South African1982HM045812 VereenigingSouth AfricaEast Central South African1956HM045792 S27-African prototypeTanzaniaEast Central South African1953AF369024 Ross low-psgTanzaniaEast Central South African1953HM045811 TR206/H804187BrazilAsian2014KP164572 0811aTwIndonesiaAsian2008FJ807891 2008900245-BDG E1IndonesiaAsian2008KC879577 MY021IMR/06/BPMalaysiaAsian2006EU703762 PhH15483PhilippinesAsian1985HM045790 Gibbs 63-263IndiaAsian1963HM045813 TH35ThailandAsian1958HM045810 HD 180760SenegalWest African2005HM045817 37997SenegalWest African1983AY726732 Fig. 1Neighbour-Joining phlylogenetic analysis of sequences obtained from DENV positive samples using Tamura-Nei model with 1000 bootstrap reiterations. For each sequence, GenBank accession number/viral genotype/country of origin of the infection/year of the infection are reported. Sequences characterized in this study are indicated by a black square. The bars indicate the percentage of diversity. Bootstrap values over 80% obtained from 1000 replicate trees are shown for key nodes. **a**: DENV-1 genotypes; **b**: DENV-2 genotypes; **c**: DENV-3 genotypes; **d**: DENV-4 genotypes Fig. 2Neighbour-Joining phlylogenetic analysis of sequences obtained from CHIKV positive samples using Tamura-Nei model with 1000 bootstrap reiterations. For each sequence, GenBank accession number/viral genotype/country of origin of the infection/year of the infection are reported. Sequences characterized in this study are indicated by a black square. The bars indicate the percentage of diversity. Bootstrap values over 80% obtained from 1000 replicate trees are shown for key nodes

Discussion {#Sec17}
==========

In this study, we present the results of laboratory diagnosis of imported Arbovirus infections in Italy, in the period from July 2014 to October 2015. As it is well known, dengue is endemic throughout the tropics and subtropics, and its global prevalence has grown dramatically in recent years. Indeed, we found that DENV infection was the most frequently detected imported arboviral infection among our patients. Moreover, all four known DENV genotypes were detected. An increase in imported CHIKV cases was also observed, as already documented in Spain, mainland France, and Northern Italy, along with the first identification of ZIKV imported cases; both findings are attributable to the recent dramatic spread of both CHIKV and ZIKV in previously unaffected areas \[[@CR27], [@CR42]--[@CR44]\]. The continuous expansion of the areas with Arbovirus circulation, together with the dispersion of *Aedes* mosquitoes *spp.*, which are known or might be competent vectors \[[@CR45]\], may increase the risk of outbreaks also in temperate climate areas. In Italy, the widespread presence of *Ae. albopictus* throughout the country, and the recent introduction and spread of new species \[[@CR46], [@CR47]\], make this risk particularly high. However, no autochthonous transmission chains have been recorded in our country in the period between July 2014 and October 2015.

The widespread circulation of CHIKV and ZIKV in areas until recently known to be endemic only for DENV represents a matter of concern for the potential risk of introduction in temperate regions, and raises significant diagnostic issues. In particular, problems related to the broad cross-reactivity of closely related viral agents, and the lack of well validated and standardized, commercially available tests (as it is for ZIKV), or the non-optimal performance of available tests, particularly when different viral agents co-circulate in the same areas, need to be addressed. To this regard, ZIKV imported cases are increasingly being reported, as a consequence of the continuous spread of the infection in south and central America \[[@CR16], [@CR48]\], leading to an increase in the requests for diagnosis. Criticisms in ZIKV diagnosis have been outlined recently \[[@CR16]\], particularly for pregnant women \[[@CR49]\], following the alert for the possible association between this infection and neonatal microcephaly \[[@CR50]\].

From this scenario, the need for a careful evaluation of the diagnostic tools available for these infections clearly emerges. At this aim, in this work we have defined "our" criteria for case definition (Table [3](#Tab3){ref-type="table"}) on the basis of the results of the diagnostic tests routinely used in our laboratory. However, it must be underlined that the final case definition for each patient is up to the clinician, and at this aim criteria are well defined in the National Plan for Arbovirus surveillance \[[@CR30], [@CR31]\] issued annually by the Italian Ministry of Health.

Molecular approaches for the diagnosis of viral infections are the most rapid as well as sensitive and specific. Moreover, sequencing and phylogenetic analysis of detected viruses can contribute to the knowledge of circulating viral strains and of the degree of their genetic variability. However, as suggested by our data, the use of molecular techniques is limited by the short duration of viremia during the course of the infection. With respect to serological diagnosis, we assessed some limitations in the sensitivity and/or specificity of the ELISA IgM kits routinely used in our laboratory, and also some degree of discrepancy with IgM results obtained by different laboratories. We have estimated approximately 14.5% of false positive and 11.0% false negative results for DENV, and approximately 9.6% of false negatives for CHIKV. Although the main purpose of our study was not a detailed analysis of the performances of different IgM detection systems, our data strengthen the need to confirm the diagnosis of cases defined as probable on the basis of IgM tests results. With respect to the PRNT, we have defined as "borderline" results those in which 50%,(i.e., less than 80%) of plaque reduction was observed. We found that b.l. PRNT results can be obtained in different situations. In most cases, they can be observed in samples collected soon after the onset of symptoms, and can be considered as an early, specific, response to the infection. In some cases, however, b. l. PRNT results can be due to infection by a closely related virus: we have observed a b.l. PRNT result for ZIKV in a DENV confirmed, DENV PRNT positive case; and, conversely, a DENV b.l. PRNT result in a ZIKV confirmed, ZIKV PRNT positive case. Indeed, even if PRNT is considered the most specific test, there can be some degree of cross-reactivity, thus b.l. PRNT results should always be considered cautiously. Finally, few cases showed b.l. PRNT results for several viruses (such as DENV, CHIKV and WNV), which probably represents a non-specific response of unknown origin, maybe due to an underlying, still undefined pathology.

Conclusion {#Sec18}
==========

DENV infection was the most frequently diagnosed cause of illness among travelers, and all four genotypes were detected. An increase in imported CHIKV cases and the first imported ZIKV cases were detected. Major diagnostic issues highlighted in our study are sensitivity limitations of molecular tests, and the importance of PRNT to confirm serological results for the differential diagnosis of Arboviruses. Moreover, the implementation of a network of laboratories involved in surveillance activities throughout the country may greatly improve the preparedness for a rapid a proper recognition of a possible autochthonous outbreak. Finally, the continuous evaluation of laboratory findings in the context of surveillance activities can be of great importance for the development of novel diagnostics, and for field evaluation of the impact of viral diseases, also in view of vaccine development and use.

*Ae*.

:   *Aedes*

b.l.

:   Border line

CHIKV

:   Chikungunya virus

DENV

:   Dengue virus

ISS

:   Istituto Superiore di Sanità

NRLA

:   National Reference Laboratory for Arboviruses

PCR

:   Polymerase chain reaction

PRNT

:   Plaque Reduction Neutralization Test

WHO

:   World Health Organization

WNV

:   West Nile virus

ZIKV

:   Zika virus
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